Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Phase I clinical trial commences in Germany for insomnia compound

Feb. 2, 1999

No Comments

NeuroSearch commences phase II clinical trials of potential antidepressant

Feb. 2, 1999

No Comments

Vanguard Medica and Elan seek regulatory approval of Miguard in the U.S.

Feb. 2, 1999

No Comments

AMPA receptor antagonists in the pipeline at Schering

Feb. 2, 1999

No Comments

Neurobiological Technologies awarded SBIR grant for Xerecept development

Feb. 1, 1999

No Comments

European Commission approves Betaseron for treatment of SPMS

Jan. 29, 1999

No Comments

Antipsychotic development candidate selected from carbazolone series by Spanish scientists

Jan. 29, 1999

No Comments

Neotrofin shows positive results in phase II trial for Alzheimer's disease

Jan. 29, 1999

No Comments

Angiotech to study paclitaxel for yet another new indication

Jan. 28, 1999

No Comments

OP-1 protects against cerebral infarct in rat model

Jan. 28, 1999

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Neurology/psychiatric
RSS

Phase I clinical trial commences in Germany for insomnia compound

NeuroSearch commences phase II clinical trials of potential antidepressant

Vanguard Medica and Elan seek regulatory approval of Miguard in the U.S.

AMPA receptor antagonists in the pipeline at Schering

Neurobiological Technologies awarded SBIR grant for Xerecept development

European Commission approves Betaseron for treatment of SPMS

Antipsychotic development candidate selected from carbazolone series by Spanish scientists

Neotrofin shows positive results in phase II trial for Alzheimer's disease

Angiotech to study paclitaxel for yet another new indication

OP-1 protects against cerebral infarct in rat model

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Neurology/psychiatric RSS

Neurology/psychiatric
RSS